☆ 4.3 Article

High or increasing serum NfL is predictive of impending multiple sclerosis relapses

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Related references

Note: Only part of the references are listed.

Review Clinical Neurology

Serum neurofilament light in MS: The first true blood-based biomarker?

Simon Thebault et al.

Summary: This review highlights the potential role of serum neurofilament light chain (sNfL) as a promising blood-derived biomarker in the routine management of multiple sclerosis (MS) patients. Various studies have shown associations of sNfL levels with outcomes of interest, including inflammatory activity, progression, treatment response, and prediction/prognosis, supporting its potential as an objective, convenient, and cost-effective adjunct to clinical assessment. Future research is needed to further explore the limitations of sNfL and pave the way for other promising biomarkers for precision medicine in MS patients.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Article Medicine, General & Internal

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study

Timo Uphaus et al.

Summary: This study found that sNfL levels at baseline predict relapse-free disability progression in patients with multiple sclerosis, and further discriminates patients with secondary progressive MS (SPMS) at follow-up.

EBIOMEDICINE (2021)

Add to Collection

Review Neurosciences

Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation

Simon Thebault et al.

Summary: Measurement of serum neurofilament light chain concentration (sNfL) shows promise as a convenient, cost-effective, and meaningful tool for multiple sclerosis (MS) prognostication and disease activity monitoring. However, before integrating this test into routine clinical practice, several hurdles related to clinical validity and analytical validity need to be addressed. Overcoming these obstacles is crucial for the current and future role of sNfL assays in MS clinical practice.

FRONTIERS IN NEUROSCIENCE (2021)

Add to Collection

Article Clinical Neurology

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity

Heidi Hogel et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

Add to Collection

Article Clinical Neurology

A roadmap to precision medicine for multiple sclerosis

Tanuja Chitnis et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

Add to Collection

Article Clinical Neurology

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

Ludwig Kappos et al.

JAMA NEUROLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis

Simon Thebault et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Multidisciplinary Sciences

Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

Xavier Ayrignac et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Blood Neurofilament Light Chain: The Neurologist's Troponin?

Simon Thebault et al.

BIOMEDICINES (2020)

Add to Collection

Article Clinical Neurology

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

Jens Kuhle et al.

NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Ahmed Abdelhak et al.

FRONTIERS IN NEUROLOGY (2019)

Add to Collection

Article Medicine, Research & Experimental

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

Antonio Uccelli et al.

TRIALS (2019)

Add to Collection

Article Clinical Neurology

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS

Katja Akguen et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)

Add to Collection

Article Clinical Neurology

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

Christian Barro et al.

BRAIN (2018)

Add to Collection

Article Multidisciplinary Sciences

Serum GFAP as a biomarker for disease severity in multiple sclerosis

A. Abdelhak et al.

SCIENTIFIC REPORTS (2018)

Add to Collection

Article Clinical Neurology

Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis

Tanuja Chitnis et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)

Add to Collection

Article Clinical Neurology

Neurofilament light chain predicts disease activity in relapsing-remitting MS

Kristin N. Varhaug et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)

Add to Collection

Article Clinical Neurology

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

Lenka Novakova et al.

NEUROLOGY (2017)

Add to Collection

Article Computer Science, Information Systems

Modeling repeated time-to-event health conditions with discontinuous risk intervals - An example of a longitudinal study of functional disability among older persons

Z. Guo et al.

METHODS OF INFORMATION IN MEDICINE (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.